AQST Aquestive Therapeutics

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in March 2025 as follows:

  • Leerink's Global Biopharma Conference 2025 to take place from March 10th to March 12th: fireside chat to take place on Monday, March 10th at 4:20-4:50pm EST; management will also be available for 1x1 meetings
  • Barclays 27th Annual Global Healthcare Conference to take place from March 11th to March 13th; management will also be available for 1x1 meetings on March 12th

A webcast of the presentation at the Leerink's Global Biopharma Conference 2025 will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics, Inc.

Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for the treatment of possible various dermatology conditions, including alopecia areata. For more information, visit and follow us on LinkedIn.

Forward Looking Statement

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement for clinical development and approval by the U.S. Food and Drug Administration of the Company’s product candidates, including AQST-109 for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 for the treatment of possible various dermatology conditions, including alopecia areata. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Contact:

Brian Korb

astr partners



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE

Aquestive Therapeutics to Report First Quarter 2025 Financial Results ...

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market...

 PRESS RELEASE

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharm...

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17. About Aquestive Therapeutics, Inc.Aquestive is a...

 PRESS RELEASE

Aquestive Therapeutics Announces Positive Topline PK Results from its ...

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film Reports positive pharmacokinetic (PK) results from the recently completed pediatric study for Anaphylm™ Completes submission of its New Drug Application (NDA) for Anaphylm to the FDA; NDA acceptance expected in Q2 2025 WARREN, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patient...

 PRESS RELEASE

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Finan...

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment communit...

 PRESS RELEASE

Aquestive Therapeutics to Participate in Two Upcoming Conferences in M...

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in March 2025 as follows: Leerink's Global Biopharma Conference 2025 to take place from March 10th to March 12th: fireside chat to take place on Monday...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch